ClinicalTrials.gg
Active, not recruitingNCT05704244Updated Sep 2, 2026

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

A Phase 3 interventional study of FE 999326 in Bladder Cancer, sponsored by Ferring Pharmaceuticals. Active, not recruiting at 24 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Urinary Bladder Neoplasms with a site in Japan — 20 open to participants now, 34 under way, 16 of them phase 3. Urinary Bladder Neoplasms · Japan.

Enrollment
50th of 52
25 · median 465
Started
2022
with 2 others
Phase 3
23 of 57
3 open now
Primary completion
2029-11
later than 28 of 33 live
Registered
39th of 57
by date

Among the 57 studies in Urinary Bladder Neoplasms with a site in Japan, this one is the 50th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2022, is one of 23 in phase 3, reaches primary completion later than 28 of the 33 other live ones, and was the 39th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

20 of the 57 studies in Urinary Bladder Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Urinary Bladder Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.

03

Conditions studied

  • Bladder Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have at entry, confirmed by a pathology report:

    1. Carcinoma in situ (CIS) only
    2. Ta/T1 high-grade disease with concomitant CIS or
    3. Ta/T1 high-grade disease without concomitant CIS
  • Subjects who did not respond to BCG treatment and have a persistent high-grade recurrence within 12 months after BCG was initiated, and those who despite an initial complete response to BCG, relapse with CIS within 12 months of their last intravesical treatment with BCG or relapse with high-grade Ta/T1 NMIBC within 6 months of their last intravesical treatment with BCG.
  • >2 years, in the opinion of the investigator
  • (ECOG) status 2 or less
  • Absence of concomitant upper tract urothelial carcinoma or urothelial carcinoma within the prostatic urethra
  • Subjects with prostate cancer on active surveillance at low risk for progression, defined as prostate-specific antigen (PSA) \<10 ng/dL

Exclusion criteria

Exclusion Criteria:

  • Current or previous evidence of muscle invasive (muscularis propria) or disease presented at the screening visit.
  • Current systemic therapy for bladder cancer
  • Current or prior treatment for BCG unresponsive NMIBC or any other investigational drug within 1 month prior to screening
  • Current or prior pelvic external beam radiotherapy within 5 years of entry
  • Use of other adenovirus vector medications, including COVID-19 vaccines, within 2 weeks before and after instillation
  • History of of other organ system within past 5 years, except treated basal cell carcinoma or squamous cell carcinoma of the skin and ≤pT2 upper tract urothelial carcinoma at least 24 months after nephroureterectomy.
  • Subjects who cannot hold instillation for 1 hour
  • Subjects who cannot tolerate intravesical dosing or intravesical surgical manipulation
  • Intravesical therapy within 8 weeks prior to beginning trial treatment, with the exception of:

    • Cytotoxic agents when administered as a single instillation immediately following a TURBT procedure
    • Previous intravesical BCG therapy
  • Systemic therapy within 3 months prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    FE 999326

    Drug: FE 999326

Interventions

  • 75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter

    Also known as: nadofaragene firadenovec

06

What researchers measure

Primary outcomes

  1. Whether or not a subject with CIS (with or without concomitant high-grade Ta or T1 papillary disease) responds to treatment, defined as complete response at any time after first administration of FE 999326

    A subject with CIS (with or without concomitant high-grade Ta or T1 papillary disease) has achieved a complete response at an efficacy assessment if urine cytology is negative and there are no lesions on cystoscopy. If biopsy of the bladder is performed, this must be negative.

    Time frame: At Month 12 assessment

Secondary outcomes

  1. Duration of complete response in subjects with CIS (with or without concomitant high-grade Ta or T1 papillary disease) who show a complete response at any time after first administration of FE 999326

    Time frame: Up to 5 years

  2. Whether or not a subject with high-grade Ta or T1 papillary disease (without concomitant CIS) responds to treatment, defined as absence of recurrence of high-grade disease

    Time frame: Up to 4 years

  3. Duration of event-free survival in subjects with high-grade Ta or T1 papillary disease (without concomitant CIS) and in subjects with CIS (with or without papillary disease)

    Time frame: Up to 5 years

  4. Incidence of cystectomy

    Time frame: Up to 4 years

  5. Time to cystectomy

    Time frame: Up to 4 years

  6. Overall survival

    Time frame: Up to 5 years

  7. Concentration of FE 999326-specific DNA levels in urine

    Time frame: Up to day 1 of month 4 after start of treatment; and 3, 6, 9 and 12 months after last dose (up to 5 years after start of treatment)

  8. Type, incidence, relatedness and severity of treatment emergent adverse events

    Time frame: Up to 5 years

07

Study locations

24 sites
  • Ferring Investigational Site
    Nagakute-shi, Aichi-ken, Japan
  • Ferring Investigational Site
    Nagoya, Aichi-ken, Japan
  • Ferring Investigational Site
    Narita-shi, Chiba, Japan
  • Ferring Investigational Site
    Matsuyama, Ehime, Japan
  • Ferring Investigational Site
    Fukuoka, Fukuoka, Japan
  • Ferring Investigational Site
    Hiroshima, Hiroshima, Japan
  • Ferring Investigational Site
    Hakodate-shi, Hokkaido, Japan
  • Ferring Investigational Site
    Sapporo, Hokkaido, Japan
  • Ferring Investigational Site
    Hitachi-shi, Ibaraki, Japan
  • Ferring Investigational Site
    Tsukuba, Ibaraki, Japan
  • Ferring Investigational Site
    Kawasaki-shi, Kanagawa, Japan
  • Ferring Investigational Site
    Yokohama, Kanagawa, Japan
  • Ferring Investigational Site
    Nankoku-shi, Kochi, Japan
  • Ferring Investigational Site
    Tsu, Mie-ken, Japan
  • Ferring Investigational Site
    Sendai, Miyagi, Japan
  • Ferring Investigational Site
    Matsumoto-shi, Nagano, Japan
  • Ferring Investigational Site
    Kashihara-shi, Nara, Japan
  • Ferring Investigational Site
    Okayama, Okayama-ken, Japan
  • Ferring Investigational Site
    Takatsuki-shi, Osaka, Japan
  • Ferring Investigational Site
    Bunkyo-ku, Tokyo, Japan
  • Ferring Investigational Site
    Minato-ku, Tokyo, Japan
  • Ferring Investigational Site
    Mitaka-shi, Tokyo, Japan
  • Ferring Investigational Site
    Toyama, Toyama, Japan
  • Ferring Investigational Site
    Wakayama, Wakayama, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Nov 2029, 83 months after the start.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's planned 83 months is above that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2022
First posted
Jan 30, 2023
StartActual
Dec 21, 2022
Primary completionEst.
Nov 30, 2029
CompletionEst.
Nov 30, 2029
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05704244
Responsible party
Sponsor
First posted
Jan 30, 2023
Start date
Dec 21, 2022
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Sep 2, 2026

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nadofaragene firadenovec

Start the discussion